The value and updates of surgical treatment for advanced gastrointestinal stromal tumors
10.3969/j.issn.1005-6483.20250595
- VernacularTitle:晚期胃肠间质瘤手术治疗的价值和相关进展
- Author:
Miao YAN
1
;
Yi LU
1
;
Xinhua ZHANG
1
Author Information
1. 510000 广州,中山大学附属第一医院胃肠外科
- Publication Type:Journal Article
- Keywords:
advanced gastrointestinal stromal tumor;
surgery;
survival prognosis;
tyrosine kinase inhibitors
- From:
Journal of Clinical Surgery
2025;33(6):661-664
- CountryChina
- Language:Chinese
-
Abstract:
Imatinib is the standard first-line treatment for advanced gastrointestinal stromal tumors(GISTs),but half of patients develop drug resistance within 18 to 24 months.In recent years,more and more retrospective studies have shown that surgery can be used as an adjunct therapy to tyrosine kinase inhibitors(TKIs),delay the onset of drug resistance,and improve patient prognosis.Patients with advanced GISTs who have benefited from targeted therapy or have limited progression and those who are expected to achieve R0/R1 resections may benefit from surgery.Due to the lack of high-quality research evidence,surgical decision-making,patient selection,and the sequence of targeted therapy are still under controversy.The surgical treatment of advanced GISTs should be carried out in a case-by-case manner under the framework of multidisciplinary team guidance.
